Aptevo Therapeutics (NASDAQ:APVO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report released on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.

Aptevo Therapeutics Price Performance

Shares of NASDAQ APVO opened at $0.17 on Thursday. The business’s 50 day moving average is $0.37 and its two-hundred day moving average is $1.27. Aptevo Therapeutics has a 52-week low of $0.14 and a 52-week high of $21.56.

Aptevo Therapeutics (NASDAQ:APVO) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.93) by $0.26. Sell-side analysts expect that Aptevo Therapeutics will post -4.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics at the end of the most recent quarter. 8.06% of the stock is owned by institutional investors and hedge funds.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.